No profile data available.
AtriCure, Inc. (ATRC) is a healthcare company in the heart treatment equipment industry, based in Mason, United States, with about 1,350 full-time employees.
It reported revenue of $534.53 million for fiscal year 2025, up 14.9% from fiscal year 2024, and net income of -$11.45 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $153.60 million, up 12.8% from a year before. United States was its largest region in fiscal year 2025, with 81% of revenue. Its market capitalization was $2.84 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
AtriCure, Inc. engages in the development, manufacture, and sale of devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, the Asia-Pacific, and internationally.
AtriCure reported $534.53 million in revenue for fiscal year 2025, up 14.9% from $465.31 million in fiscal year 2024. In Q2 2026 revenue was $153.60 million.
United States: 81% of revenue by region in fiscal year 2025, followed by Europe (12%).
$2.84 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (heart treatment equipment) include LivaNova PLC (LIVN), Pulse Biosciences, Inc. (PLSE), iRhythm Technologies, Inc. (IRTC), Kestra Medical Technologies, Ltd. (KMTS).